Course Director

Costas Lallas, MD


Anne Calvaresi, NP

Edouard Trabulsi, MD

Accredited by

American Urological Association

Course Description

After completing this activity, participants will be able to:

1. Describe the standard of care chemotherapy regimens for genitourinary malignancies.
2. Recall both historic and newer immunotherapy options in the treatment of genitourinary malignancies, including recently approved checkpoint inhibitors and antibody-drug conjugates.
3. Outline the mechanism of action of common chemotherapy and immunotherapy regimens for genitourinary malignancies.
4. Recognize and manage the adverse events and survivorship issues related to these malignancies and agents.
5. List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.

Activity Details

Credit Types:CME
Credit Amount:1.50 Credits
Release Date:2020-Jul-29
Expiration Date:2021-Jul-29
Registration Required:Yes

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.